APA (7th ed.) Citation

JW, N., A, S., M, G., FL, L., B, F., RD, G., . . . E, F. (2024). Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study. JTO clinical and research reports, 5(10), 100666. https://doi.org/10.1016/j.jtocrr.2024.100666

Chicago Style (17th ed.) Citation

JW, Neal, et al. "Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study." JTO Clinical and Research Reports 5, no. 10 (2024): 100666. https://doi.org/10.1016/j.jtocrr.2024.100666.

MLA (9th ed.) Citation

JW, Neal, et al. "Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study." JTO Clinical and Research Reports, vol. 5, no. 10, 2024, p. 100666, https://doi.org/10.1016/j.jtocrr.2024.100666.